Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of intrathecal RO7234292 in manifest Huntington's disease
2018-002987-14Phase 3Unknown
- Sponsor
- Roche
- Start
- Feb 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing RO7234292 intrathecal with Placebo intrathecal (2 arms). Primary endpoint: Change from baseline in composite Unified Huntington's Disease Rating Scale score at Week 101. Status: unknown.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2018-002987-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002987-14.